leisure time -WSS

leisure time

author：Wikipedia 2025-09-28 06:09:08 - browse：97

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： In his State of the Union, Biden takes clear aim at 'Big Pharma'

WSS

Apple Vision Pro: A first look at health apps on the new VR headset

ARCH Venture Partners is raising $3 billion for a life sciences fund

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Just how do doctors, lawmakers, and the public define abortion?

Cognito secures funding to test medical device for Alzheimer's

Commercial surrogacy can be ethical, despite pope’s claims

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

How to save PrEP access — and even expand it

Headspace, Meta partner to launch VR meditation app for Quest

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Even great ERs can’t make up for American health disparities

Heart attack and stroke risk calculators need revising

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Hepatitis C has a cure — but many Americans still lack access to it

FDA drug safety: Singulair case shows systemic surveillance flaws

Bright Health sells Medicare Advantage business to Molina

The problem with charging patients to message their doctors

focus

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Air quality improving but still lags in Black, Hispanic communities

Change Healthcare cyberattack prompts Medicare loan program

With psoriasis trial ahead, Alumis raises $259 million

Even great ERs can’t make up for American health disparities

UnitedHealth quietly bought dozens of outpatient centers

focus

knowledge

focus

hotspot